Surgical Innovations Group (LSE:SUN) Research & Development: £0.00 Mil (TTM As of Dec. 2025)


What is Surgical Innovations Group Research & Development?

Surgical Innovations Group LSE:SUN Research & Development is £0.00 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Surgical Innovations Group's Research & Development for the six months ended in Dec. 2025 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00 Mil.

Surgical Innovations Group  (LSE:SUN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Surgical Innovations Group Research & Development Related Terms

Surgical Innovations Group Research & Development Historical Data

* Premium members only.

The historical data trend for Surgical Innovations Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surgical Innovations Group Research & Development Chart

Surgical Innovations Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.97 1.16 1.10 1.15 1.26

Surgical Innovations Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Surgical Innovations Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
Surgical Innovations Group (LSE:SUN) has a Research & Development of £0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Surgical Innovations Group and its competitors.
Is Surgical Innovations Group's Research & Development too high?
Surgical Innovations Group's current Research & Development is £0.00 Mil.
How does Surgical Innovations Group's Research & Development compare to ABT and SYK?
Surgical Innovations Group's Research & Development of £0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Surgical Innovations Group and its competitors. Surgical Innovations Group's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Innovations Group stock overvalued right now?
Based on GuruFocus' analysis, Surgical Innovations Group (LSE:SUN) is currently considered Possible Value Trap. The stock's GF Value™ is £0.01, compared to a current price of £0.00 — trading 52.5% below its estimated fair value. The current Research & Development is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Surgical Innovations Group (LSE:SUN), the current Research & Development is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surgical Innovations Group Business Description

Address Clayton Wood House, 6 Clayton Wood Bank, Leeds, GBR, LS16 6QZ
Surgical Innovations Group PLC is involved in the design, development, manufacture, and sale of devices for use in minimally invasive surgery (SI Brand), along with its label products through original equipment manufacturer (OEM) relationships, including precision engineering markets (PE). The Company's operating segments are SI Brand, OEM, and Distribution. The majority of its revenue is generated from the SI Brand segment, which is involved in the research, development, manufacture, and distribution of SI-branded minimally invasive devices. Geographically, the group derives a majority of its revenue from the United Kingdom, followed by Europe, the United States, the Asia-Pacific region, and the Rest of the world.